论文部分内容阅读
GlaxoWellcome公司获得美国FDA许可上市其舒马曲坦（sumatriptan）鼻喷雾剂。本品上市的商品名为ImitrexNasalSpray，适用于不论是否有先兆的成人偏头痛发作的急性治疗；但不用于预防偏头痛。舒马曲坦的皮下注射剂和片剂早已在美国上市，鼻喷雾剂1997年IO月份上市。尽管皮下注
GlaxoWellcome Acquired US FDA Approval for Its Sumatriptan Nasal Spray. This product is marketed under the brand name Imitrex Nasal Spray for acute treatment of migraine attacks in adults with or without aura; but not for the prevention of migraine. Sumatriptan subcutaneous injections and tablets have long been available in the United States, nasal sprays listed in October 1997. Despite the subcutaneous injection